Cell biology

Camena Bioscience Appoints Dr Nicola Thompson as Chair of the Board

Retrieved on: 
Wednesday, December 6, 2023
Science, Biotechnology, Research, Pharmaceutical, Environment, Health, Genetics, Green Technology, Acquisition, Cell biology, DNA, Therapy, Gene, Chair, Chairperson, Astellas Pharma, University College London, GSK, Roche, Growth, Doctor of Philosophy, Pharma, Pharmaceutical industry, Amphisbaena, Camena

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, today announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors.

Key Points: 
  • Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, today announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors.
  • Dr Steve Harvey, CEO, Camena Bioscience commented: "Nicola is a successful CEO and Chair and a fantastic addition to the Board.
  • Camena Bioscience enables researchers to ‘write’ DNA with the same confidence and ease with which we can ‘read’ DNA.
  • Dr Nicola Thompson, Chair of the Board, Camena Bioscience, added: “I am delighted to join the Company as its Chair at this pivotal stage of growth.

Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

Retrieved on: 
Monday, December 4, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, General Health, Science, Oncology, Mitochondrial disease, Anatomy, Cell biology, DNA, Gene editing, PMM, IND, Liver, Patient, University, CRISPR, Mitochondrial myopathy, Doctor of Philosophy, CTA, A-DNA, Manuscript, MELAS, Mutation, Cell, Nature Metabolism, Precision BioSciences, Vaccine, Neurology

For mitochondrial diseases, what makes ARCUS such an elegant and simple tool is that it is a single protein that both recognizes and eliminates the mutant mitochondrial DNA,” said Jeff Smith, Ph.D., Chief Research Officer of Precision BioSciences.

Key Points: 
  • For mitochondrial diseases, what makes ARCUS such an elegant and simple tool is that it is a single protein that both recognizes and eliminates the mutant mitochondrial DNA,” said Jeff Smith, Ph.D., Chief Research Officer of Precision BioSciences.
  • “Today’s publication further validates the ability of ARCUS to overcome the limitations of CRISPR-based gene editing technologies for treating mitochondrial disease and eliminating mutated mitochondrial DNA with high specificity to improve overall mitochondrial function.
  • By eliminating the mutant mitochondrial DNA and allowing the wild-type mitochondrial DNA to repopulate, mitoARCUS drives a shift toward healthy mitochondrial DNA, a process known as shifting heteroplasmy.
  • “To date, there are no curative treatments for mitochondrial diseases, so a gene editing approach is a novel way to offer hope to the patients suffering from mitochondrial myopathy.

Global Multiomics (Single-cell, Bulk) Market Research 2023-2030: Decreasing Costs and Growing Investments from Private/Public Sectors - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, Pharmaceutical, Health, Cell biology, Research, Investment, Application, Genomics, USD, Automation, Drug discovery, Software, Cancer, Roche, Amazon Web Services, Growth, Foundry, Pharmaceutical industry, Video game, Fine chemical

In addition, rising competition in the market owing to increasing demand from pharmaceutical & biotechnology companies and academic research institutions is also anticipated to propel the market growth over the forecast period.

Key Points: 
  • In addition, rising competition in the market owing to increasing demand from pharmaceutical & biotechnology companies and academic research institutions is also anticipated to propel the market growth over the forecast period.
  • With the improvement in technologies, the cost of omics technologies is anticipated to reduce, which can increase the accessibility of datasets to researchers, consequently driving market growth.
  • Thus, the decreasing costs are anticipated to increase the accessibility of omics technologies to researchers and clinicians.
  • The growing investments and funding from private and public participants are anticipated to boost the demand for multi-omics products and services.

bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post

Retrieved on: 
Tuesday, November 28, 2023
Research, Medical Devices, Surgery, Genetics, Biotechnology, Radiology, Pharmaceutical, Health, Science, Oncology, BIAF, ASCB, Cell biology, Student, Cell, European, EMBO, European Molecular Biology Organization, Society, Government, Education, Pharmaceutical industry, Management

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that David Elzi, Ph.D., bioAffinity Technologies Vice President of Research, has been named to the Membership Committee of the American Society for Cell Biology (ASCB).

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that David Elzi, Ph.D., bioAffinity Technologies Vice President of Research, has been named to the Membership Committee of the American Society for Cell Biology (ASCB).
  • First organized in 1960, ASCB is an international organization of cell biologists dedicated to advancing scientific discovery, advocating sound research policies, improving education, promoting professional development and increasing diversity in the scientific workforce.
  • The Membership Committee is responsible for implementing programs and services to meet the needs of the ASCB’s membership and support its mission and strategic plan, including recruiting new members and retaining current members.
  • Aimed at students, post-docs and research scientists, the roundtable will be held Dec. 3, 2023, at 1:15 p.m.

Durin Technologies, Inc., Appoints CEO

Retrieved on: 
Wednesday, November 22, 2023
Health, Neurology, Mental Health, Medical Devices, Alzheimer's disease, Thermo Fisher Scientific, Cell biology, U.S.–Canada Team Tournament (Go), Roche, Multimedia, GE HealthCare, Marketing, University, Neurodegenerative disease, Growth, Doctor of Philosophy, University of Hamburg, HIV disease progression rates, Medical device, Management, Dwarves in Middle-earth

Durin Technologies, Inc., an innovator in neurodegenerative disease diagnostic test development and commercialization, today announced the appointment of Dr. Mert Sahin as Chief Executive Officer.

Key Points: 
  • Durin Technologies, Inc., an innovator in neurodegenerative disease diagnostic test development and commercialization, today announced the appointment of Dr. Mert Sahin as Chief Executive Officer.
  • View the full release here: https://www.businesswire.com/news/home/20231122887173/en/
    Mert Sahin, PhD Joins Durin Technologies as CEO.
  • (Photo: Business Wire)
    Dr. Sahin is a highly accomplished business executive with an impressive track record of success in the life sciences sector.
  • He brings to Durin more than 20 years of experience in life sciences, pharmaceuticals, and medical devices, where he has demonstrated expertise in formulating and executing strategic go-to-market plans resulting in exceptional growth.

Deepcell Garners Industry Recognition for Disruptive AI-Driven Approach to Single Cell Morphology Analysis

Retrieved on: 
Tuesday, November 14, 2023
Technology, Health, Other Health, Pharmaceutical, Artificial Intelligence, Stem Cells, Oncology, Other Science, Research, Software, Infectious Diseases, Genetics, Science, Data Management, Axon, Cell biology, Deep learning, Entrepreneurship, Artificial intelligence, Cell, Intelligence, Biomedical Research, Biotechnology, Developmental biology, EST, Society, AMP, Live single-cell imaging, News, Mary K. Estes, Single-cell analysis, Microscope, Boston

Deepcell , a pioneer in artificial intelligence (AI)-powered single-cell analysis to fuel deep biological discoveries, today shared the news of two significant industry recognitions as it prepares for upcoming scientific meetings.

Key Points: 
  • Deepcell , a pioneer in artificial intelligence (AI)-powered single-cell analysis to fuel deep biological discoveries, today shared the news of two significant industry recognitions as it prepares for upcoming scientific meetings.
  • Earlier this year, Deepcell launched the REM-I platform , a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, Human Foundation Model, and Axon data suite.
  • By bringing together single cell imaging, sorting, and high-dimensional analysis, the REM-I platform catalyzes new methods of discovery in a wide range of fields including cancer biology, developmental biology, stem cell biology, gene therapy and functional screening, among others.
  • Deepcell’s REM-I platform was selected as "Cell Imaging Product of the Year," one of only four breakthrough innovations in the field of cell biology, in the third annual BioTech Breakthrough Awards.

4Moving Biotech forms its Scientific Advisory Board of World-Renowned Knee Osteoarthritis Experts

Retrieved on: 
Friday, November 10, 2023
Research, Hospitals, Clinical Trials, Biotechnology, Other Health, Managed Care, Health, Pharmaceutical, Science, Orthopedic surgery, Cell biology, Hospital, University of Leeds, Multimedia, Shanghai Sixth People's Hospital, University, Trial of the century, Physiology, CMO, Coronavirus Scientific Advisory Board, Radiology, Medical school, Paracelsus Medical University, Microsurgeon, Pharmaceutical industry, Anatomy, Biostatistics, Medicine, Boston

4Moving Biotech, a subsidiary of 4P-Pharma, announces establishing an international Scientific Advisory Board in anticipation of its knee osteoarthritis drug candidate's phase 2b clinical trial.

Key Points: 
  • 4Moving Biotech, a subsidiary of 4P-Pharma, announces establishing an international Scientific Advisory Board in anticipation of its knee osteoarthritis drug candidate's phase 2b clinical trial.
  • Professor Francis Berenbaum, CMO of 4Moving Biotech, will lead the work of this scientific advisory board.
  • The Scientific Advisory Board will bring deep knowledge and experience from clinical research, academia, and industry to better serve people suffering from knee osteoarthritis.
  • 4Moving Biotech has responded to this challenge with an innovative research program to explore the potential of intra-articular GLP-1 analogs for knee osteoarthritis treatment.

Stem Cell Therapy Contract Manufacturing Market Report 2023-2033 - Advances in Cell Biology and Regenerative Medicine Propels Stem Cell Therapy Market

Retrieved on: 
Thursday, December 14, 2023
Cell biology, Research, Catalent, Organization, Regenerative medicine, AbbVie, Retail, Lonza

DUBLIN, Dec. 14, 2023 /PRNewswire/ -- The "Stem Cell Therapy Contract Manufacturing Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 14, 2023 /PRNewswire/ -- The "Stem Cell Therapy Contract Manufacturing Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • In an insightful new research publication, the burgeoning stem cell therapy contract manufacturing market is analyzed in extensive detail, projecting a surpassing of US$2.75 billion in value for the year 2023 alone.
  • The latest findings highlight the rapid evolution of the stem cell therapy contract manufacturing market, bolstered by advances in cell biology and regenerative medicine.
  • The report presents granular forecasts spanning numerous market segments including scale of operation, size of contract manufacturer, and stem cell types, among others.

Cells Move in Groups Differently Than They Do When Alone

Retrieved on: 
Wednesday, December 13, 2023
NYU Langone Health, National Institutes of Health, Cell biology, Tissue, Protein, Multimedia, Transforming protein RhoA, Zebrafish, Movement, Biology, Bacteria, NYU, Cancer, Human, Doctor of Philosophy, Current Biology, Cell, American Heart Association, Mobile phone

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- A protein that helps generate the force needed for single cells to move works differently in cells moving in groups, a new study shows.

Key Points: 
  • NEW YORK, Dec. 13, 2023 /PRNewswire/ -- A protein that helps generate the force needed for single cells to move works differently in cells moving in groups, a new study shows.
  • Zebrafish are a major model in the study of development because they are transparent and share cellular mechanisms with humans.
  • The current study found that the cells in the primordium instead activate RhoA in pulses in the front of the cells where it does two jobs.
  • "The machinery suggests that the movement of single cells and groups of cells is similar, but that RhoA contributes to that machinery differently in each case.

Live Cell Imaging Market to Reach $5.2 Billion, Globally, by 2032 at 8.2% CAGR: Allied Market Research

Retrieved on: 
Tuesday, December 12, 2023
B cell, HCS, Cell biology, Observation, Research, Fluorophore, Investment, Biotechnology, Growth, Regenerative medicine, Drug discovery, Cell division, Drug development, Fine chemical, Mobile phone

PORTLAND, Ore., Dec. 12, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Live Cell Imaging Market by Product Type (Instruments, Accessories and Consumables and Software), Application (Cell Biology, Stem Cells, Developmental Biology, and Drug Discovery), Technology (Time-lapse Microscopy, Fluorescence Resonance Energy Transfer (FRET), Fluorescence Recovery After Photobleaching (FRAP), High-Content Screening (HCS), and Other Technologies) and End User (Pharmaceutical and Biotechnological Companies, Academic and Research Institutes, Contract Research Organizations, and Others): Global Opportunity Analysis and Industry Forecast, 2023–2032". According to the report, the global live cell imaging industry generated $2.3 billion in 2022 and is anticipated to generate $5.2 billion by 2032, witnessing a CAGR of 8.2% from 2023 to 2032.

Key Points: 
  • Moreover, it hampers investments in live cell imaging technology development, slowing down innovation and the introduction of advanced imaging systems.
  • Diseases and health concerns persist regardless of economic conditions, potentially leading to sustained demand for live cell imaging technologies in critical areas such as disease research, diagnostics, and drug development.
  • This is attributed to increase in funding allocations research studies, promoting adoption of advanced live cell imaging technologies for varied biological studies.
  • In addition, robust funding environment, coupled with supportive government initiatives, has propelled the adoption of innovative imaging techniques such as live cell imaging in academic and research institutions.